Eli Lilly's latest Zyprexa settlement will not affect civil or criminal investigations pending over Zyprexa from state attorneys general and federal prosecutors, which are continuing.
Only if one assumes that the FDA sees the drug industry as its client can some sense be made of December 13th meeting of the FDA’s Psychopharmacologic Drugs Advisory Committee in Silver Springs, Maryland.
The question is: will Eli Lilly succeed, once again, to divert public attention from the revelations contained in its internal documents about the company's illegal marketing practices and its failure to warn about lethal risks posed by its product?
NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation."
Expert Scientists, Psychiatrists, a Primary Care Physician, a Leading Attorney, will shed light on FDA’s Review of selected data Re: Antidepressants and Adult Suicidality One day prior to FDA’s Advisory Committee Hearing, December 13.
An eye opening article by Jeanne Lenzer, “NIH Secrets,” in The New Republic (below), should make the new Congress sit up and take notice!
The Baltimore Sun reports (below) that in a paper scheduled for publication in the journal Epidemiology and Infection, a Harvard University-led team proposes that a vitamin D deficiency caused by inadequate winter sun exposure may predispose people to infection.
FDA's slip-shod approval of defective, harmful drugs, accompanied by rubber stampped endorsements by compromised FDA advisory committees may be reaching a boiling point.
Medicare Rx Drug Bill Shaped by Drug Industry Blocks Elderly Bargaining Power – NYT Fri, 5 Sep 2003 A drug industry lobbyist is quoted in The New York Times stating: “Having both houses of Congress Republican-controlled was great. Like in Monopoly, when you get to add hotels.” The Medicare prescription…
Merck / Johnson & Johnson/ Lilly-Zyprexa: $690 Million settlement / a Flowering of Diabetes Drugs Fri, 10 Jun 2005 A cluster of news reports about three pillars of the pharmaceutical industry– Merck, Eli Lilly, and Johnson & Johnson–leave no doubt that this industry has shown its disregard for the welfare…
Pfizer Nears Drug Settlement Sun, 16 Mar 2003 A 7-year lawsuit filed by Dr. David Franklin, the former Harvard fellow turned whistle blower, may be reaching a resolution. The suit accuses Warner Lambert (now Pfizer) of illegally promoting the epilepsy drug, Neurontin, for conditions not approved or tested. His lawsuit…
Disingenous Remarks from AMA President on Tort Reform – letter BMJ / NYT Test a Lawyer’s Ingenuity Sun, 6 Mar 2005 Responding to an article in the BMJ about President Bush’s bill to restrict class action suits for medical malpractice-http://bmj.bmjjournals.com/cgi/content/full/330/7490/499-c – the president of the American Medical Association, Dr. John…
